Towards a more comprehensive approach for a total economic assessment of vaccines?

References

• Drummond M, Jonsson B, Rutten F. The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy. 1997;40(3):1–15. ​​
   Web of Science ®Google Scholar
• Drummond MF, Schwartz JS, Jonsson B, et al. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care. 2008;24(3):244–258.
   PubMed Web of Science ®Google Scholar
• Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics. 2008;26(3):191–215.
   PubMed Web of Science ®Google Scholar
• Van Damme P, Beutels P. Economic evaluation of vaccination. Pharmacoeconomics. 1996;9(Suppl 3):8–15.
   Google Scholar
• Lieu T, Meltzer MI, Messonnier M. Guidance for health economics studies presented to the Advisory Committee on Immunization Practices (ACIP) 2007. [ cited 2017 Apr 14]. Available from: www.cdc.gov/vaccines/acip/committe/downloads/economic-studies-guidance.pdf
   Google Scholar
• Walker DG, Hutubessy R, Who BP. Guide for standardisation of economic evaluations of immunization programmes. Vaccine. 2010;28(11):2356–2359.
   PubMed Web of Science ®Google Scholar
• Walker DG, Beutels P. WHO guide for standardization of economic evaluations of immunization programmes. (Switzerland):WHO, department of Immunization, Vaccines and Biologicals; Geneva (Switzerland): WHO; 2008. (no. WHO/IVB/08.14). ​​
   Google Scholar
• Ricciardi W, Toumi M. National Immunization Therapeutic Advisory Group: it is time for experience sharing and best practice learning. J Mark Access Health Policy. 2015;3:29276. ​​
   Google Scholar
• Postma MJ, Standaert BA. Economics of vaccines revisited. Hum Vaccin Immunother. 2013;9(5):1139–1141.
   PubMed Web of Science ®Google Scholar
• Merriam-Webster. Prevention definition [n.d. Web]; 2016 [ cited 2017 Apr 14]. Available from: https://www.merriam-webster.com/dictionary/prevention
   Google Scholar
• Faust HS, Menzel PT. Prevention vs treatment, what’s the right balance? 1st ed. Oxford: Oxford University Press; 2011.
   Google Scholar
• Whitney CG, Zhou F, Singleton J, et al. Benefits from immunization during the vaccines for children program era - USA, 1994–2013. MMWR Morb Mortal Wkly Rep. 2014;63(16):352–355.
   PubMed Web of Science ®Google Scholar
• Aspinall R, Del Giudice G, Effros R, et al. Challenges for vaccination in the elderly. Immun Ageing. 2007;4:1–9.
   PubMedGoogle Scholar
• Ada GL. The immunological principles of vaccination. Lancet. 1990;335(8688):523–526.
   PubMed Web of Science ®Google Scholar
• Roush SW, Murphy TV. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the USA. JAMA. 2007;298(18):2155–2163.
   PubMed Web of Science ®Google Scholar
• Nelson B. Public health: behind a vaccine. Nature. 2015;520(7549):711–713.
   Web of Science ®Google Scholar
• Turnock B. Public health, what it is and how it works. 5th ed. Chicago: Jones and Bartlett Learning; 2012.
   Google Scholar
• Salisbury DM, Beverley PC, Miller E. Vaccine programmes and policies. Br Med Bull. 2002;62:201–211.
   Web of Science ®Google Scholar
• Verberk JDM, Bruijning-Verhagen P, de Melker HE. Rotavirus in the Netherlands. Bilthoven (The Netherlands): RIVM; 2017. (no. Report 2017–0021). ​​
   Google Scholar
• Vijgen S, Busch M, De Wit G, et al. Economische evaluatie van preventie - Kansen voor het Nederlandse volksgezondheidsbeleid [Economic evaluation of prevention -opportunities for Dutch public health policy]. Bilthoven: Centrum voor Preventie en Zorgonderzoek (PZO), Rijksinstituut voor Volksgezondheid en Milieu (RIVM); 2005. (no. Report 270091001). Dutch.
   Google Scholar
• Cashin C, Arias D, Bloom DE, et al. Immunization financing: a resource guide for advocates, policymakers, and program managers. Washington (DC): Results for Development; 2017.
   Google Scholar
• SAGE. Principles and considerations for adding a vaccine into a national immunization programme: from decision to implementation and monitoring. (Switzerland): WHO, Department of Immunization, Vaccines and Biologicals. Geneva (Switzerland); 2014. ​​
   Google Scholar
• CNN-Money. Rwanda’s hospitals will use drones to deliver medical supplies 2016. [ cited 2017 Apr 14]. Available from: http://money.cnn.com/2016/10/13/technology/rwanda-drone-hospital/
   Google Scholar
• Wagner K, White J, Saliba V. Human Papillomavirus (HPV) vaccine coverage in England, 2008/9 to 2013/14: a review of the full six years of the three-dose schedule. London: Public Health England; 2015. (PHE publications gateway number: 2014797). [ cited 2017 Apr 14]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/412264/HPV_Vaccine_Coverage_in_England_200809_to_201314.pdf
   Google Scholar
• KFF.org. 2015. The HPV vaccine: access and use in the U.S. fact sheet. Menlo Park: The Henry J. Kaiser Family Foundation. [ cited 2017 Apr 14]. Available from: http://www.tandf.co.uk/journals/authors/style/reference/tf_NLM.pdf
   Google Scholar
• Frank J, Jepson R, Williams A. Basic principles of successful and unsuccessful prevention. In: Frank J, Jespon R, Williams A, editors. Disease prevention: a critical toolkit. Oxford: Oxford University Press; 2016. p. 1–19.
   Google Scholar
• Berridge V. Public health a very short introduction. 1st ed. Oxford: Oxford University Press; 2016.
   Google Scholar
• Arora S. On epidemiologic and economic transitions: a historical view. In: Lopez-Casasnovas G, Rivera B, Currais L, editors. Health and economic growth. 1st ed. Cambridge (MA): MIT; 2005. p. 197–238.
   Google Scholar
• Bynum W. The history of medicine, a very short introduction. 1st ed. Oxford: Oxford Unversity Press; 2008.
   Google Scholar
• Richards C, Emori TG, Peavy G, et al. Promoting quality through measurement of performance and response: prevention success stories. Emerg Infect Dis. 2001;7(2):299–301.
   Web of Science ®Google Scholar
• Herzog B. History of tuberculosis. Respiration. 1998;65(1):5–15.
   Web of Science ®Google Scholar
• Nordqvist C. What are signs and symptoms and why do they matter? 2016 [ cited 2017 Apr 14]. Available from: http://www.medicalnewstoday.com/articles/161858.php
   Google Scholar
• Porter ME. What is value in health care? N Engl J Med. 2010;363:2477–2481.
   PubMed Web of Science ®Google Scholar
• Standaert B, Alwan A, Strens D, et al. Improvement in hospital Quality of Care (QoC) after the introduction of rotavirus vaccination: an evaluation study in Belgium. Hum Vaccin Immunother. 2015;11(9):2266–2273.
   PubMed Web of Science ®Google Scholar
• Watt G. The inverse care law today. Lancet. 2002;360(9328):252–254.
   PubMed Web of Science ®Google Scholar
• Luce BR, Drummond M, Jonsson B, et al. EBM, HTA, and CER: clearing the confusion. Milbank Q. 2010;88(2):256–276.
   PubMed Web of Science ®Google Scholar
• Duclos P. National Immunization Technical Advisory Groups (NITAGs): guidance for their establishment and strengthening. Vaccine. 2010;28(Suppl 1):A18–A25.
   PubMed Web of Science ®Google Scholar
• NITAG. Health council of the Netherlands - terms of reference 2017. [ cited 2017 April 14]. Available from: http://www.nitag-resource.org/media-center/document/755
   Google Scholar
• Fuguitt D, Wilcox SJ. Cost-benefit analysis of public sector decision makers. 1st ed. Westport (CT): Quorum Books; 1999.
   Google Scholar
• Nagle T, Hogan J. The strategy and tactics of pricing. 4th ed. Upper Saddle River (NJ): Pearson Prentice Hall; 2006.
   Google Scholar
• Schoonveld E. The price of global health. 1st ed. Farnham: Gower Publishing Limited; 2011.
   Google Scholar
• Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977;296(13):716–721.
   PubMed Web of Science ®Google Scholar
• Bala MV, Zarkin GA, Mauskopf JA. Conditions for the near equivalence of cost-effectiveness and cost-benefit analyses. Value Health. 2002;5(4):338–346.
   Web of Science ®Google Scholar
• Johnson R, Adamowicz W. Valuation and cost-benefit analysis in health and environmental economics. In: McIntosh E, Clarke P, Frew E, editors. Applied methods of cost-benefit analysis in health care. Handbooks in health economic evaluation series. Oxford: Oxford Unversity Press; 2010. p. 79–96. ​​
   Google Scholar
• Marsh K, Phillips CJ, Fordham R, et al. Estimating cost-effectiveness in public health: a summary of modelling and valuation methods. Health Econ Rev. 2012;2(1):17.
   Google Scholar
• Drummond M, Sculpher M, Torrance G, et al. Cost-utility analysis. In: Drummond M, Sculpher M, Torrance G, et al., editors. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005. p. 137–210.
   Google Scholar
• Bärnighausen T, Berkley S. Reassessing the value of vaccines. Lancet. 2014;2(5):e251–e252.
   Web of Science ®Google Scholar
• Martin A, Cottrell S. Estimating utility in rotavirus gastroenteritis in children under five in the UK (abstract PIH19). Value Health. 2006;9(6):A258.
   Web of Science ®Google Scholar
• Huppertz HI, Forster J, Heininger U, et al. The Parental Appraisal of the Morbidity of Diarrhea in Infants and Toddlers (PAMODI) Survey. Clin Pediatr (Phila). 2008;47(4):363–371.
   PubMed Web of Science ®Google Scholar
• Scarbrough Lefebvre CD, Terlinden A, Standaert B. Dissecting the indirect effects caused by vaccines into the basic elements. Hum Vaccin Immunother. 2015;11(9):2142–2157.
   PubMed Web of Science ®Google Scholar
• Miller M, Barrett S, Henderson DA. Control and eradication. In: Jamison DT, Breman JG, Measham AR, et al., editors. Disease control priorities in developing countries. 2nd ed. Oxford:Oxford University Press; 2006. p.1163–1177.
   Google Scholar
• Klepac P, Funk S, Hollingsworth TD, et al. Six Challenges in the eradication of infectious diseases. Epidemics. 2015;10:97–101. ​​
   Web of Science ®Google Scholar
• Dort T, Schecroun N, Standaert B. Improving the quality of care in paediatric hospital environment by optimizing budget allocation between investment in vaccination and future institutional development. Value in Health. 2016;19(3):A106.
   Web of Science ®Google Scholar
• Drummond M, Chevat C, Lothgren M. Do we fully understand the economic value of vaccines? Vaccine. 2007;25(32):5945–5957.
   PubMed Web of Science ®Google Scholar
• Standaert B, Van de Mieroop E, Nelen V. Exploring the potential impact of rotavirus vaccination on work absenteeism among female administrative personnel of the City of Antwerp through a retrospective database analysis. BMJ Open. 2015;5(6):e007453.
   PubMed Web of Science ®Google Scholar
• Hauber AB, Standaert B, Poulos C. Development of a survey to quantify parents’ priorities for vaccinating children against rotavirus. Value Health. 2014;17(7):A681.
   Web of Science ®Google Scholar
• Baltussen R, Niessen L. Priority setting of health interventions: the need for multi-criteria decision analysis. Cost Eff Resour Alloc. 2006;4(14):1–9.
   Google Scholar
• Geyman JP. Moral Hazard and consumer-driven health care: a fundamentally flawed concept. Int J Heatlh Serv. 2007;37(2):333–351.
   Web of Science ®Google Scholar
• Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value Health. 2009;12(Suppl 1):S5–S9.
   PubMed Web of Science ®Google Scholar
• Weinstein MC, Fineberg HV. Clinical decision analysis. Philadelphia: WB Saunders Company; 1980.
   Google Scholar
• Mason JM. Cost-per-QALY league tables: their role in pharmacoeconomic analysis. Pharmacoeconomics. 1994;5(6):472–481.
   Web of Science ®Google Scholar
• van Doorslaer E, Wagstaff A, van der Burg H, et al. Equity in the delivery of health care in Europe and the US. J Health Econ. 2000;19(5):553–583.
   PubMed Web of Science ®Google Scholar
• Cleemput I, Neyt M, Thiry N, et al. Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions. Int J Technol Assess Health Care. 2011;27(1):71–76.
   PubMed Web of Science ®Google Scholar
• Culyer A. Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use. Health Econ Policy Law. 2016;11(4):415–432.
   PubMed Web of Science ®Google Scholar
• Paulden M, Claxton K. Budget allocation and the revealed social rate of time preference for health. Health Econ. 2012;21(5):612–618.
   Web of Science ®Google Scholar
• JCVI. Joint Committee on vaccination and immunisation. Minutes of the meeting held on Wednesday 13 February 2008 at 10.30; 2017 [ cited 2017 Apr 14]. Available from: http://webarchive.nationalarchives.gov.uk/20120907090205/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@ab/documents/digitalasset/dh_095069.pdf
   Google Scholar
• Chisholm D, Evans D. Economic evaluation in health: saving money or improving care? J Med Econ. 2007;10(3):325–337.
   Google Scholar
• Standaert B, Ethgen O, Emerson R, et al. Comparing cost-effectiveness results for a vaccine across different countries worldwide: what can we learn? Adv Ther. 2014;31(10):1095–1108.
   Web of Science ®Google Scholar
• Cleemput I, Neyt M, Thiry N, et al. Threshold values for cost-effectiveness in health care. Brussels: Belgian Health Care Knowledge Centre; 2008. (no. KCE reports 100 C).
   Google Scholar